ArticlePsychopharmacology2022
Dopamine D1 receptors mediate methamphetamine-induced dopaminergic damage: involvement of autophagy regulation via the AMPK/FOXO3A pathway.
Article in Psychopharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Molecular mechanisms of programmed cell death in methamphetamine-induced neuronal damage.Frontiers in pharmacology · 2022Pooled it
- Dopamine D1-like and Angiotensin II Type 1 Receptors Counter-Regulate Autophagy and Cell Proliferation in Rat Embryonic Thoracic Vascular Smooth Muscle Cells.International journal of molecular sciences · 2026Article
- Molecular Mechanisms of Hippocampal Synaptic Plasticity Disruption Induced by Chronic Methamphetamine Exposure: A Narrative Review.Cellular and molecular neurobiology · 2026Review
- Modulation of autophagy by melatonin and its receptors: implications in brain disorders.Acta pharmacologica Sinica · 2025Review
- The Common Denominators of Parkinson's Disease Pathogenesis and Methamphetamine Abuse.Current neuropharmacology · 2024Review
- The role of Foxo3a in neuron-mediated cognitive impairment.Frontiers in molecular neuroscience · 2024Review
- A novel microRNA, novel-m009C, regulates methamphetamine rewarding effects.Molecular psychiatry · 2022Article
- Methamphetamine Use: A Narrative Review of Adverse Effects and Related Toxicities.Health psychology research · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
rationaleClinical studies have revealed that methamphetamine abuse increases risk for developing Parkinson's diseases. It is thus important to elucidate the mechanisms by which methamphetamine damages dopaminergic neurons.
objectivesThe present study was designed to elucidate the role of the dopamine D1 receptor in methamphetamine-mediated dopaminergic neuronal damage and its underlying mechanisms.
methodsMice were treated for 4 days with vehicle, methamphetamine, or the D1 agonist SKF38393 and then assessed for locomotion and performance in the pole and rotarod tests. Cellular indices of autophagy, LC3, P62, and Beclin-1, tyrosine hydroxylase, and the AMPK/FOXO3A pathway were analyzed in striatal tissue from treated mice, in PC12 cells, and in D1 receptor mutant mice.
resultsRepeated treatment with a relatively high dose of methamphetamine for 4 days induced both loss of dopaminergic neurons and activation of autophagy in the striatum as evidenced by increased expression of LC3 and P62. However, such treatment did not induce either loss of dopaminergic neurons or activation of autophagy in D1 receptor knockout mice. D1 receptor-mediated activation of autophagy was also confirmed in vitro using dopaminergic neuronal PC12 cells. Further studies demonstrated that the AMPK/FOXO3A signaling pathway is responsible for D1 receptor-mediated activation of autophagy.
conclusionsThe present data indicate a novel mechanism for methamphetamine-induced dopaminergic neuronal damage and reveal an important role for D1 receptors in the neurotoxicity of this drug.
Indexed as
Identifiers
35190859What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.